Breakthrough pain in patients with multiple myeloma: a secondary analysis of IOPS MS study

Eur Rev Med Pharmacol Sci. 2023 Feb;27(3):1134-1139. doi: 10.26355/eurrev_202302_31219.

Abstract

Objective: The aim of this study was to characterize breakthrough pain (BTcP) in patients with multiple myeloma (MM).

Patients and methods: This was a secondary analysis of a large multicenter study of patients with BTcP. Background pain intensity and opioid doses were recorded. The BTcP characteristics, including the number of BTcP episodes, intensity, onset, duration, predictability, and interference with daily activities were recorded. Opioids prescribed for BTcP, time to achieve a meaningful pain relief after taking a medication, adverse effects, and patients' satisfaction were assessed.

Results: Fifty-four patients with MM were examined. In comparison with other tumors, in patients with MM BTcP was more predictable (p=0.04), with the predominant trigger being the physical activity (p<0.001). Other BTcP characteristics, pattern of opioids used for background pain and BTcP, satisfaction and adverse effects did not differ.

Conclusions: Patients with MM have their own peculiarities. Given the peculiar involvement of the skeleton, BTcP was highly predictable and triggered by movement.

Publication types

  • Multicenter Study

MeSH terms

  • Analgesics, Opioid / therapeutic use
  • Breakthrough Pain* / complications
  • Breakthrough Pain* / drug therapy
  • Fentanyl / therapeutic use
  • Humans
  • Multiple Myeloma* / drug therapy
  • Neoplasms* / drug therapy
  • Pain Management
  • Patient Satisfaction

Substances

  • Analgesics, Opioid
  • Fentanyl